The overall goal of the Cancer and Immunity Program is to provide new scientific insights into the relationships between immune system and tumors and to define target molecules and strategies for new immune-based therapies for cancer. Specific scientific goals of the Cancer and Immunity Program are: (1) to explore the relationship between tumors and leukocytes in mouse models of cancer to gain insights into the ability of the immune system to promote or deter tumorigenesis;(2) to use mouse models of cancer for preclinical studies of novel immune-based therapies, such as blocking newly discovered inhibitory regulators of the immune system, and therapeutic vaccines;(3) to identify molecules in the immune system that regulate the ability of the innate and adaptive immune system to mediate anti-tumor activity, without eliciting severe autoimmunity;(4) to define signaling pathways through immune receptors affecting cell survival and apoptosis, which may serve as therapeutic targets for cancer;(5) to study the relationship between viral infections and malignancy, particularly in immunodeficient patients with HIV infection, and to develop new approaches to the prevention and treatment of malignancy in this population;and (6) to conduct clinical trials of new immune-based immunotherapeutics in cancer, with a focus on prostate cancer, and study the immune response in individual undergoing therapy to potentially identify new targets for antigen-specific therapeutic vaccines. The Program consists of 25 faculty from 11 departments in the School of Medicine. The Program has $20,640,449 Total peer reviewed support for the last budget year. The Program has 5% intra-programmatic and 30% inter-programmatic publications.
| Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131: |
| Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228 |
| Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
| Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
| Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
| Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
| An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
| Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
| Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607 |
| An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794 |
Showing the most recent 10 out of 192 publications
